Multiparametric Assays for Accelerating Early Drug Discovery

Trends Pharmacol Sci. 2020 May;41(5):318-335. doi: 10.1016/ Epub 2020 Mar 27.


Drug discovery campaigns are hampered by substantial attrition rates largely due to a lack of efficacy and safety reasons associated with candidate drugs. This is true in particular for genetically complex diseases, where insufficient knowledge of the modulatory actions of candidate drugs on targets and entire target pathways further adds to the problem of attrition. To better profile compound actions on targets, potential off-targets, and disease-linked pathways, new innovative technologies need to be developed that can elucidate the complex cellular signaling networks in health and disease. Here, we discuss progress in genetically encoded multiparametric assays and mass spectrometry (MS)-based proteomics, which both represent promising toolkits to profile multifactorial actions of drug candidates in disease-relevant cellular systems to promote drug discovery and personalized medicine.

Keywords: CRISPR/Cas9; barcoding; complex diseases; compound profiling; patient-derived disease model; phenotypic screening.

Publication types

  • Review